A recent meta-analysis of these studies showed that PD-L1 was expressed in 35% of prostate cancers; PD-L1 expression and PD-L1 methylation were both associated with poor biochemical recurrence-free survival and PD-L1 was expressed at high levels preferentially in high Gleason score tumors and AR-positive cases [392]. The gene discussed is AR; the disease is Familial prostate cancer.